BioCentury
ARTICLE | Clinical News

Imbruvica, Venclexta combo leads to responses with no detectable MRD in Phase II for CLL

June 15, 2018 7:20 PM UTC

AbbVie Inc. (NYSE:ABBV) said 23 of the first 30 evaluable patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) in the Phase II CAPTIVATE (PCYC-1142) trial achieved a response with no detectable minimal residual disease (MRD) after six cycles of treatment with Imbruvica ibrutinib plus Venclexta venetoclax. In 14 evaluable patients who completed 12 cycles of combination treatment, 13 achieved responses with no detectable MRD as measured in peripheral blood and 12 achieved responses with no detectable MRD as measured in bone marrow. The data were presented at the American Society of Clinical Oncology (ASCO) meeting in Chicago.

The trial has enrolled 164 treatment-naïve CLL or SLL patients to receive once-daily 420 mg oral Imbruvica alone for three 28-day cycles, followed by Imbruvica plus Venclexta for at least 12 cycles...